Intellia Halts Major Trial Following Severe Liver Incident, Shares Plummet
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Should l Buy CRSP?
Source: Benzinga
Trial Pause: Intellia Therapeutics has paused patient dosing and screening in its Phase 3 MAGNITUDE trials for its CRISPR therapy, nexiguran ziclumeran (nex-z), due to a serious liver-related adverse event in a participant.
Patient Safety Commitment: The company is working with regulators and medical experts to assess the incident, emphasizing its commitment to patient safety and planning to safely resume enrollment.
Promising Phase 1 Results: Long-term follow-up data from a Phase 1 trial showed significant reductions in transthyretin protein levels and improvements in neuropathy scores among patients treated with nex-z.
Market Impact: Following the announcement of the trial pause, Intellia's shares fell by over 43%, reflecting investor concerns about the implications for the ongoing MAGNITUDE trials.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRSP is 68.88 USD with a low forecast of 40.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
11 Buy
7 Hold
0 Sell
Moderate Buy
Current: 45.880
Low
40.00
Averages
68.88
High
105.00
Current: 45.880
Low
40.00
Averages
68.88
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cathie Wood's Investment Outlook for 2026
- Joby Aviation Investment: Despite Joby Aviation's stock plummeting 17% after announcing a $1.2 billion stock and convertible note offering, it still achieved a 33% return over the past year, indicating market confidence in the long-term potential of electric vertical takeoff and landing aircraft, with Wood's increased stake signaling her bullish outlook.
- Kodiak AI Challenges: Kodiak AI's market cap has dropped from $2.5 billion to $1.6 billion, and while its technology in autonomous trucking is promising, the current operation of only 10 commercial vehicles suggests insufficient market acceptance, making Wood's investment a bet on future growth potential.
- CRISPR Therapeutics Outlook: CRISPR set multiple milestones for 2026, with its Casgevy treatment generating over $100 million in revenue last year; despite its stock being down 76% from its all-time high five years ago, plans to expand treatment usage may attract renewed investor interest.
- Market Sentiment Analysis: Wood's decision to increase her holdings during market downturns reflects her confidence in long-term growth, and despite facing stock price volatility and market concerns in the short term, her investment strategy may yield substantial returns in the future.
See More
CRISPR Therapeutics: A Promising Biotech Investment
- Gene Editing Potential: CRISPR Therapeutics focuses on developing therapies for hard-to-treat diseases, with CTX211 aiming to restore insulin production in Type 1 diabetes patients, which could significantly enhance patient quality of life and open new market opportunities.
- Anticoagulant Innovation: SRSD107 is designed to address the side effects of existing anticoagulants, and if successful, it could provide a safer treatment option for 40 million high-risk patients, potentially transforming the anticoagulant market landscape.
- Cholesterol Management: The development of CTX310 aims to lower LDL cholesterol and triglycerides, targeting a vast market of 40 million patients; if it can achieve one-time treatment, it will greatly enhance patient compliance and reduce long-term healthcare costs.
- Market Risk Consideration: While CRISPR Therapeutics presents high return potential, clinical and regulatory risks could impact stock prices, necessitating careful evaluation of market acceptance and associated costs of its gene-editing therapies by investors.
See More
Wall Street Focuses on Earnings and Commodity Prices
- Earnings Impact: Meta's strong sales forecast and $100 billion AI investment plan drove its stock up in after-hours trading, while Microsoft fell due to slowing cloud growth and soft margin guidance, indicating a divergence in market sentiment towards tech stocks.
- Commodity Market Fluctuations: Gold prices nearing $5600 and silver surpassing $120 reflect investors' demand for safe-haven assets amid economic uncertainty, simultaneously boosting trading volumes in related ETFs like GLD and SLV.
- Market Sentiment: Despite Nasdaq and S&P 500 futures rising by 0.4% and 0.3% respectively, retail sentiment towards SPY and QQQ remains extremely bearish, suggesting ongoing investor concerns about market outlook.
- Upcoming Earnings Reports: Investors are keenly awaiting Apple's earnings report, particularly for insights on iPhone demand and AI roadmap updates, while Western Digital and SanDisk are also set to report today, potentially impacting the data storage sector.
See More
CRISPR Therapeutics Faces Renewed Pressure Amid Insider Sales
- Insider Selling Impact: CEO Samarth Kulkarni sold over 90,000 shares over three days last week, unsettling investors despite retaining approximately 85,000 shares, leading to a stock price drop of over 10%.
- Weak Revenue Growth: The company reported only $890,000 in revenue for Q3, significantly below the consensus estimate of $8.06 million, which further eroded investor confidence and negatively impacted stock performance.
- Momentum Score Decline: CRISPR's momentum score in Benzinga's stock rankings fell from 76.81 to 50.97, indicating poor price trends and volatility across multiple time frames, reflecting unfavorable short- and medium-term price movements.
- Fund Holding Changes: Frequently featured in Cathie Wood's funds, CRISPR's declining momentum score may lead to reduced confidence among investors, potentially affecting its holdings in these funds.
See More
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
See More
Ark Invest Unveils 2026 Big Ideas, Focus on AI and Genomics
- AI Agents Theme: Ark Invest's first ARKmoji hints at agentic AI, with users divided on its meaning; the option 'AI Agent Takeover' received 37.5% support, indicating strong market interest in AI technologies that could impact stocks like Palantir.
- Genomics Potential: The second ARKmoji features a DNA helix, with 34.7% of votes for 'Molecular Diagnostics', highlighting investment opportunities in genomics, potentially benefiting related stocks like Crispr Therapeutics.
- Space Race Trend: The third ARKmoji depicts a rocket, with 55% of users selecting 'Reusable Rockets', reflecting enthusiasm for space technology investments, with holdings like Rocket Lab poised for growth.
- Robotics Development: The final ARKmoji shows a robot, with 59% voting for the 'Robotics' theme, indicating strong market interest in robotics technology, with Tesla's Optimus robot project likely to be a future growth driver.
See More
Cathie Wood's Investment Outlook for 2026
- Joby Aviation Investment: Despite Joby Aviation's stock plummeting 17% after announcing a $1.2 billion stock and convertible note offering, it still achieved a 33% return over the past year, indicating market confidence in the long-term potential of electric vertical takeoff and landing aircraft, with Wood's increased stake signaling her bullish outlook.
- Kodiak AI Challenges: Kodiak AI's market cap has dropped from $2.5 billion to $1.6 billion, and while its technology in autonomous trucking is promising, the current operation of only 10 commercial vehicles suggests insufficient market acceptance, making Wood's investment a bet on future growth potential.
- CRISPR Therapeutics Outlook: CRISPR set multiple milestones for 2026, with its Casgevy treatment generating over $100 million in revenue last year; despite its stock being down 76% from its all-time high five years ago, plans to expand treatment usage may attract renewed investor interest.
- Market Sentiment Analysis: Wood's decision to increase her holdings during market downturns reflects her confidence in long-term growth, and despite facing stock price volatility and market concerns in the short term, her investment strategy may yield substantial returns in the future.
See More
CRISPR Therapeutics: A Promising Biotech Investment
- Gene Editing Potential: CRISPR Therapeutics focuses on developing therapies for hard-to-treat diseases, with CTX211 aiming to restore insulin production in Type 1 diabetes patients, which could significantly enhance patient quality of life and open new market opportunities.
- Anticoagulant Innovation: SRSD107 is designed to address the side effects of existing anticoagulants, and if successful, it could provide a safer treatment option for 40 million high-risk patients, potentially transforming the anticoagulant market landscape.
- Cholesterol Management: The development of CTX310 aims to lower LDL cholesterol and triglycerides, targeting a vast market of 40 million patients; if it can achieve one-time treatment, it will greatly enhance patient compliance and reduce long-term healthcare costs.
- Market Risk Consideration: While CRISPR Therapeutics presents high return potential, clinical and regulatory risks could impact stock prices, necessitating careful evaluation of market acceptance and associated costs of its gene-editing therapies by investors.
See More
Wall Street Focuses on Earnings and Commodity Prices
- Earnings Impact: Meta's strong sales forecast and $100 billion AI investment plan drove its stock up in after-hours trading, while Microsoft fell due to slowing cloud growth and soft margin guidance, indicating a divergence in market sentiment towards tech stocks.
- Commodity Market Fluctuations: Gold prices nearing $5600 and silver surpassing $120 reflect investors' demand for safe-haven assets amid economic uncertainty, simultaneously boosting trading volumes in related ETFs like GLD and SLV.
- Market Sentiment: Despite Nasdaq and S&P 500 futures rising by 0.4% and 0.3% respectively, retail sentiment towards SPY and QQQ remains extremely bearish, suggesting ongoing investor concerns about market outlook.
- Upcoming Earnings Reports: Investors are keenly awaiting Apple's earnings report, particularly for insights on iPhone demand and AI roadmap updates, while Western Digital and SanDisk are also set to report today, potentially impacting the data storage sector.
See More
CRISPR Therapeutics Faces Renewed Pressure Amid Insider Sales
- Insider Selling Impact: CEO Samarth Kulkarni sold over 90,000 shares over three days last week, unsettling investors despite retaining approximately 85,000 shares, leading to a stock price drop of over 10%.
- Weak Revenue Growth: The company reported only $890,000 in revenue for Q3, significantly below the consensus estimate of $8.06 million, which further eroded investor confidence and negatively impacted stock performance.
- Momentum Score Decline: CRISPR's momentum score in Benzinga's stock rankings fell from 76.81 to 50.97, indicating poor price trends and volatility across multiple time frames, reflecting unfavorable short- and medium-term price movements.
- Fund Holding Changes: Frequently featured in Cathie Wood's funds, CRISPR's declining momentum score may lead to reduced confidence among investors, potentially affecting its holdings in these funds.
See More
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
- Technological Acceleration: Ark Invest's report highlights that capital investment in disruptive innovation platforms could contribute 1.9 percentage points to annualized real GDP growth during this decade, emphasizing the potential of technologies like robotaxis and next-gen data centers.
- Strong ETF Performance: In 2025, Ark's Autonomous Technology & Robotics ETF and Space & Defense Innovation ETF achieved returns of 49.8% and 49.2%, respectively, showcasing the firm's ability to generate returns in emerging technology sectors.
- Bitcoin Holdings Surge: The report indicates that U.S. ETFs and public companies now hold 12% of total Bitcoin supply, with Bitcoin ETF balances up 19.7% and public company Bitcoin holdings up 73% in 2025, reflecting strong market demand for digital assets.
- Diverse Investment Opportunities: Ark Invest identifies several publicly traded companies, including Coinbase, Illumina, and Waymo, as key investment opportunities for the 2026 themes, indicating the firm's forward-looking approach to diversified investment strategies.
See More
Ark Invest Unveils 2026 Big Ideas, Focus on AI and Genomics
- AI Agents Theme: Ark Invest's first ARKmoji hints at agentic AI, with users divided on its meaning; the option 'AI Agent Takeover' received 37.5% support, indicating strong market interest in AI technologies that could impact stocks like Palantir.
- Genomics Potential: The second ARKmoji features a DNA helix, with 34.7% of votes for 'Molecular Diagnostics', highlighting investment opportunities in genomics, potentially benefiting related stocks like Crispr Therapeutics.
- Space Race Trend: The third ARKmoji depicts a rocket, with 55% of users selecting 'Reusable Rockets', reflecting enthusiasm for space technology investments, with holdings like Rocket Lab poised for growth.
- Robotics Development: The final ARKmoji shows a robot, with 59% voting for the 'Robotics' theme, indicating strong market interest in robotics technology, with Tesla's Optimus robot project likely to be a future growth driver.
See More
